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PRAZIQUANTEL AND OXAMNIQUINE IN THE TREATMENT 
OF MANSONI SCHISTOSOMIASIS 
Getúlio Leonel de REZENDE (1) 
S U M M A R Y 
A random, double-blind, parallel group clinical trial program was carried out 
to compare praziquantel, a recently developed anti-helmintic drug, and oxamniqui¬ 
ne, an already established agent for treating mansoni schistosomiasis. Both drugs 
were administered orally as a single dose, on the average, praziquantel 55 mg/kg 
and oxamniquine 16 mg/kg BWT. The diagnosis and the parasitológica! follow-up 
lasting for a minimum of six months, were based on stool examinations according 
to Kato/Katz technique. A patient was considered cured if all results were ne­
gative and if he had performed at least three post-treatment controls, each one 
comprising three stool examinations. The finding of a single S. mansoni egg in 
any stool examination indicated, a therapeutical failure. A total of 267, cases were 
treated iwith praziquantel and 272 with oxamniquine. The two groups /were homo­
geneous in regard to patients, age, clinical form of the disease, risk of reinfection 
and worm burden, relevant factors in the therapeutical response. The incidence 
and severity of untoward, effects were similar in both groups but abdominal 
distress and diarrhoea were more frequently reported under praziquantel and 
dizzines under oxamniquine (p < 0.05). In the former group a marked urticariform 
reaction was observed whereas in the latter one patient presented convulsion. 
The laboratory work-up. failed to disclose any significant alteration although the 
AST, ALT and y-GT mean values revealed a tendence to increase on the 7th day 
after oxamniquine intake. The overall parasitological cure rates were 75.5% (139/ 
184) with praziquantel and 69.8% (134/192) with oxamniquine (p > 0.05). Amongst 
the noncured aptients a reduction of 88.6% and 74.6% in the mean number of 
eggs/g of feces Was seen following the treatment with praziquantel and oxamni­
quine, respectively (p < 0.05). In conclusion, in spite of their different chemical, 
pharmacological and toxicological profiles as well as mechanisms-of-action, inclu­
sively praziquantel already had proved to be 100% active against S. mansoni 
strains resistant to oxamniquine, both drugs showed comparable tolerance and 
therapeutical efficacy. 
I N T R O D U C T I O N 
Variagated factors seem to play a relevant 
role in the evaluation of therapeutical response 
to antischistosome drugs: patients' age; worm 
burden; clinical form of the disease; risk of 
reinfection as well as duration, frequency and 
nature of parasitological control. 
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Therefore, by virtue of the variable sources 
of patients, the diversity of methodological 
approaches and the unequal criteria for asses­
sment of therapeutical efficacy, it becomes un­
feasible to confront results from distinct in­
vestigators. Consequently, in order to compare 
different drugs it is mandatory to develop 
clinical trials following a randomized, double-
blind, parallel group design. Furthermore, the 
patients should be stratified in conformity 
with the relevant factors aiming at achieving 
homogeneous groups and an uniform criteria 
for assessing parasitological cure ought to be 
followed. With the scope of comparing prazi­
quantel — a novel broad-spectrum anti-helmin-
tic agent which is active against all schistosome 
species pathogenic to man ^,36,37 —
 a n ( j oxam-
niquine — an already -well established drug for 
treating mansoni schistosomiasis3 4 — a pro­
gram comprising five clinical trials was under­
taken in Brazil 4,M,MA33. 
MATERIALS AND METHODS 
A total of 539 out-patients free from pre­
vious antischistosome treatment participated 
in the program. Seventy percent were males. 
The age varied from 8 to 65 years, with a mean 
of 20.6. One fourth consisted in children below 
15 years old and solely 9% were older than 30. 
The body weight ranged from 17 to 94 kg, in 
the average 52.4. The great majority, 93%, was 
constituted of chronic cases and 68% presented 
the intestinal form. The mean number of eggs 
per gram of feces — EPG — was 346 and the 
limits 24 and 3492. Approximately half of the 
cases eliminated from 100 to 500 eggs and just 
21% more than 500. Most of the patients, 78%-
were living away from endemic areas. Due to 
the stratification in accordance with the age, 
the clinical form of schistosomiasis, the living 
area and the worm burden as well as to the 
random allocation of patients, the two groups 
— 267 cases treated with praziquantel and 272 
with oxamniquine — turned out to be homo­
geneous concerning all relevant factors (X2 — 
p > 0.5). Table I . 
Both drugs were administered per os as a 
single dose, on the average, praziquantel 55 
mg/kg BWT (from 42 to 66) and oxamniquine 
16 mg/kg BWT (from 13 to 21). The acute cases 
were treated three months after having been 
infected. To allow a double-blind administra­
tion the two drugs were provided in capsules 
having an identical appearence but containing 
different dosages (at a ratio of 3.4) so that the 
posology was always the same for both drugs 
regardless the dose variation in relation to 
each patient's weight. The capsules were dis­
pensed within individually coded bottles. 
The diagnosis was based on stool exami­
nation by the Kato/Katz method 2 1, one week 
prior to treatment. The parasitological follow-
up period extended for a minimum of six 
months and comprised at least three controls 
— each one involved three consecutive daily 
stool examinations according to the same quan­
titative method. The arithmetic mean calculated 
from the three countings represented the result 
of each respective control. A patient was con­
sidered cured if all results were negative, the 
finding of a single S. mansoni egg in any stool 
examination indicated a therapeutical failure. 
On the day of treatment the patients were 
submitted to physical examination and symp­
tomatic evaluation. Following the drug intake 
they remained under clinical observation dur­
ing 24 hours to disclose any occurrence of 
adverse drug reaction. The following laboratory 
tests were performed prior to and one day 
after treatment in 53 patients from the pra­
ziquantel group and in 55 from the oxamniqui­
ne group: serum determination of aspartate 
aminotransferase (AST/SGOT); alamine amino­
transferase (ALT/SGPT) ; gamaglutamyl trans­
peptidase (y-GT); alkaline phosphatase; total 
bilirubin; creatinine; fast glucose; blood count­
ing of leucocytes and eosinophils; hemoglobin, 
hematocrit and urinalysis. The determination 
of the hepatic enzymes, AST, ALT and y-GT 
was repeated one week afterwards. 
RESULTS 
The overall incidence (72%) and severity 
(mostly, 85%, slight to moderate) of untoward 
effects were similar in both groups. Usually-
they appeared within the first four to six hours 
and did not last longer than one day. However, 
gastrointestinal complaints tended to be more 
frequently refered under praziquantel intake 
and neurological symptoms under oxamniqui­
ne. Table I I . 
Actually, abdominal distress and diarrhoea 
were reported at a significantly higher percen­
tage ( X 2 : p < 0.05) with praziquantel whereas 
dizziness with oxamniquine. Moreover, 'with the 
former drug a marked urticariform reaction 
was observed in two cases and fever in five. 
With the latter drug three patients complained 
of blurring of vision and one suffered an 
episode of seizure (a generalized tonic-clonic 
convulsion which lasted for a few minutes only 
and subsided spontaneously. The patient denied 
any past-history of epileptic fits). 
The laboratory work-up, besides eosino-
philia "which is commonly found in schistoso-
motic patients, failed to demonstrate any r& 
levant abnormality in both treatment groups 
in spite that the mean AST, y-GT and ALT 
values revealed a tendence to augment on the 
7th day after oxamniquine intake. Table I I I . 
On the other hand, the percentage of the 
aforementioned liver enzyme results that have 
changed from normal to abnormal post-treat­
ment with either drug was not just low but 
similar to the percentage of changes the other 
way round (Mc Nemar test : p > 0.05), Ta­
ble IV . 
Amongst the 267 patients treated with 
praziquantel 22 cases did not return for the 
parasitological follow-up and 45 had positive 
stool examination. Whilst 139 cases were consi 
dered cured, 61 with negative results were not 
evaluated since they did not complete the re­
quired three controls. In the oxamniquine 
group, with 272 patients, 58 were therapeutical 
failures and the drop-out rate was 5% (13 
cases). Sixty seven did not complete the mi­
nimum of three negative controls and were not 
evaluated taut 134 cases were considered cured. 
In "both groups the cured patients have per­
formed, in the average, 11 stool examinations 
per case. Tatale V. 
The overall parasitological cure rates were 
75.5% (139/184) with praziquantel and 69.8% 
(134/192) with oxamniquine. This difference 
(5.7%) was not statistically significant (Z test 
for difference of proportion : p > 0.05). Ta­
ble V I . 
Analysing the cure rates in relation to 
relevant factors one observes that there was a 
clear trend towards achieving poorer results 
in patients under 15 years old. Such trend was 
also found, but mainly with oxamniquine, in 
patients living at endemic areas and in those 
presenting higher worm burden. Confronting 
the two drugs regarding each factor, the re­
sults were quite comparable although in chil­
dren, in heavier infected cases and in those 
originated from endemic areas, the cure rates 
revealed a tendence to be lower in the oxamni­
quine group. Nevertheless, none of these dif­
ferences had statistical significance (Z test for 
difference of proportions : p > 0.05). 
Considering the non-cured patients, a re­
duction of 88.6% (from 386 to 44) and of 74.6% 
(from 452 to 115) in the mean number of eggs 
eliminated per gram of feces was seen following 
the treatment with praziquantel and oxamni­
quine, respectively. This difference (14%) was 
statistically significant (Mann-Whithney test : 
p < 0.05). Table V I I . 
DISCUSSION 
Taking into account the prospective con­
current comparison between praziquantel and 
oxamniquine, the homogenity of the treated 
groups and the uniformity of criteria for 
assessment of efficacy and tolerance, these 
results can be regarded as reliable evidence 
on the therapeutical properties of both schisto­
somicide agents, at these dose levels, against 
mansoni schistosomiasis in Brazil. It is worthy, 
to be noticed that their tolerance and efficacy 
were quite similar despite that praziquantel 
— an isoquinoline-pyrazino compound — and 
oxamniquine — a mirasan derivative — have 
different chemical structures, Fig. 1, as well as 
distinct pharmacological and toxicological pro­
files 1.16.17. 
Concerning tolerance one may suppose that 
many complaints particularly those involving 
the abdomen, are triggered by the interaction 
between drug and parasites and not by the 
drug itself. Inclusively, most of these symptoms 
already are present prior to treatment 3 8. Fur­
thermore, some side-effects, like skin rashes, 
might result from allergic reactions to hete-
roantigens released from the dead parasites. On 
the other hand, neuropsychiatric disturbances, 

namely convulsion, deserve careful consider­
ation. In the medical literature there are a 
few reports on the occurrence of seizures and 
electroencephalographyc alterations associated-
with the administration of oxamniquine 3,6,8,26. 
In previous clinical trials' with praziquantel 
the electroencephalogram recording studied in 
106 hepatosplenic patients did not reveal any 
significant changes W * . 
The laboratory work-up showed no im-
portant abnormality with either drug. Moreover, 
other investigators also detected no relevant 
alteration of liver function tests — AST, ALT, 
y-GT, LAP, ALH, BSP — in 160 hepatosplenic 
cases treated with praziquantel7.1 0.3 2. Actually, 
the liver function tests re-evaluated six months 
after the drug administration were improved 1 0 . 
Concerning efficacy one should not admit, 
by virtue of their comparable cure rates, that 
both drugs are equally efficacions and could 
thus be interchangeable without therapeutical 
consequences. They act through different me-
chanisms of action so that the susceptibility of 
schistosomes to each drug is not the same. 
Actually, praziquantel has proved experimen-
tally to be 100% effective against S. mansoni 
strains totally resistant to oxamniquine and 
refractory patients to repeated treatment cour-
ses with oxamniquine have become negative 
after praziquantel administration 5,13,20,22. 
The overall cure rates particularly in chil-
dren, 54.3% to 62.2%, achieved with oxamniqui-
ne and praziquantel, respectively, in the treat-
ment of mansoni schistosomiasis cannot be 
regarded as very satisfactory so that one must 
look for means to accomplish better results. 
In respect to praziquantel one may envisage 
the use of higher doses since this drug is almost 
devoided of toxicity. In previous clinical trials 
there was no consistent direct correlation bet-
ween dose increase and frequency or severity 
of untoward effects 9. 1 5. 2 3. 2 7. For treating neuro-
cysticercosis it has been employed daily doses 
of : 75 mg/kg during seven consecutive days 
in South Korea 3 0 ; 90 mg/kg for two days in 
China 3 9 and; 50 mg/kg during three weeks in 
Brazil 3 S . In the treatment of schistosomotic 
children living in endemic areas in the Brazilian 
Northeast Region two clinical trials were car-
ried out : in one 50 and 70 mg/kg, single doses 
were compared reaching cure rates of 59 and 
74%, respectively (X2
 : p < o .05) I 5 ; in the other 
a cure rate of 77% Was obtained with 80 mg/kg 
divided into two intakes four hours apart w . 
Another approach would be the administration 
of praziquantel for two to three consecutive 
days instead of a single dose intake. Such 
schedule has been successful in other human 
trematode infections — Clonorchiasis, opisto-
chiasis, paragonimiasis — which did not respond 
satisfactorily to just one day treatment 2. 2 9. 
This dose schedule is now being tried in Brazil 
showing quite promising preliminary findings 1 1. 
A different possibility refers to the con-
current administration of praziquantel plus 
oxamniquine. Indeed, a sinergistic effect has 
been proved experimentally with the combi-
nation of these two drugs and a few clinical 
trials already have been carried out in Afri-
ca 12,28,31. 
RESUMO 
Levantamento dos resultados das pesquisas clí-
nicas realizadas no Brasil, comparando o pra-
ziquantel com a oxamniquina no tratamento 
da esquistossomose mansônica. 
Um programa de avaliação terapêutica du-
plo-cega, segundo esquema de grupos paralelos 
constituidos aleatoriamente, foi realizado para 
comparar o praziquantel, um anti-helmíntico 
recentemente desenvolvido, com a oxaminiqui-
na, urna droga já consolidada no tratamento 
da esquistossomose mansônica. Ambos os medi-
camentos foram administrados por via oral em 
dose única, na média, 55 mg/kg de peso cor-
poral para o praziquantel e 16 mg/kg para a 
oxamniquina. O diagnóstico, bem como o acom-
panhamento parasitológico, com duração míni-
ma de seis meses, basearam-se em exames de 
fezes pelo método de Kato/Katz. O paciente^ 
cujos resultados foram todos negativos e quB: 
completou, pelo menos, três controles pós-tra: 
tamento, cada um compreendendo três copros-
copias, foi considerado curado. O achado de 
um unido ovo de S. mansoni em qualquer dos 
exames de fezes representou uma falha tera-
pêutica. 
Um total de 267 casos foi tratado com 
praziquantel e 272 com oxamniquina. Os dois 
grupos eram homogêneos quanto à idade dos 
pacientes, a forma clínica da doença, o risco 
de reinfecção e a carga parasitária, fatores 
relevantes na resposta terapêutica. A incidência 
e a intensidade dos efeitos indesejáveis foram 
semelhantes em ambos os grupos, embora des-
conforto abdominal e diarréia fossem signifi-
cativamente mais freqüentes com praziquantel 
e tontura com oxamniquina (p < 0.05). Ade-
mais, no primeiro grupo observou-se uma acen-
tuada reação ulticariforme e no segundo houve 
uma ocorrência de convulsão. A investigação 
laboratorial não evidenciou alterações signifi-
cativas, porém a média dos valores de AST, 
ALT e 7-GT mostrou uma tendência a aumen-
tar no sétimo dia após a administração da 
oxamniquina. A cura parasitológica global com 
praziquantel atingiu 75,5% (139/184) e com 
oxamniquina 69,8% (134/192), diferença sem sig-
nificado estatístico (p > 0.05). Dentre os pa-
cientes não curados, houve, após o tratamento, 
uma redução no número médio de ovos por 
grama' de fezes de 88,6% e 74,6% com prazi-
quantel e com oxamniquina, respectivamente, 
uma diferença estatisticamente significativa (p 
< 0.05). 
Em conclusão, apesar de serem substâncias 
com estruturas químicas diversas, de possuírem 
propriedades farmacológicas e toxicológicas 
distintas, bem como mecanismos de ação pró-
prios, inclusive tendo o praziquantel já de-
monstrado ser 100% ativo contra linhagens de 
S. mansoni resistentes à oxamniquina, ambas 
as drogas evidenciaram tolerabilidade e eficácia 
terapêutica similares. 
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